▼ FY 2025 Summary Analysis
Annual report ending Dec 31, 2025Overview and Growth
Jade Biosciences, Inc. recorded fiscal 2025 net loss of $127.41M. Diluted earnings per share were -$3.19, translating the period’s attributable earnings into the amount reported for each diluted share. A diluted share base of 31.36M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. The diluted share count was 887.5% higher than fiscal 2024, when diluted shares averaged 3.18M, adding context to the EPS comparison. Total assets stood at $349.78M, showing the scale of resources supporting revenue, earnings, liquidity, and financing.Profitability
The company recorded an operating loss of $113.54M after the reported operating expense base. After all below-operating-line items, the company recorded a net loss of $127.41M for the fiscal year. EBITDA was negative $113.52M, showing a deficit before interest, taxes, depreciation, and amortization. The pretax result was a loss of $127.35M, establishing the deficit before tax effects. The reported income-tax provision was $58.00K, the amount recognized between pretax income and the final net-income result. The net loss equaled 38.3% of period-end equity, showing the deficit relative to book capital. The net loss equaled 36.4% of period-end assets, showing the deficit relative to the asset base. The net loss widened to $127.41M from $69.63M in fiscal 2024.Liquidity and Capital Structure
The company held $349.78M of assets against $17.26M of liabilities and $332.52M of equity, revealing how the asset base was financed. The near-term balance sheet paired $348.82M of current assets with $16.54M of current liabilities at the reporting date. The current ratio was 21.09x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Reported cash and equivalents were $88.44M, separating immediately recognizable cash resources from the rest of the current-asset base. The cash balance equaled 534.7% of current liabilities, showing how much near-term coverage came from cash alone. The equity-to-assets relationship was 95.1%, placing book capital against the total resource base. Liabilities represented 4.9% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 25.3% of total assets, showing the liquid cash component within the company’s broader resource base. Compared with $72.80M in fiscal 2024, the current asset base moved 380.5% and finished higher. Compared with $69.39M in fiscal 2024, the current cash balance moved 27.5% and finished higher.Cash Flow and Earnings Quality
Cash flow from operations was an outflow of $94.69M, showing that operations absorbed cash during the period. The company spent $196.00K on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. Operating cash flow and capital spending combined to leave a $94.89M cash deficit after capital spending. The cash deficit after capital spending represented 27.1% of the period-end asset base. The operating cash outflow widened to $94.69M from $71.20M in fiscal 2024.
Based on the annual report for the fiscal year ending Dec 31, 2025.
Analysis generated .
Fundamentals Hub